Diagnosis, severity assessment, and therapy evaluation of amyloidosis using amyloid PET imaiging (Continued study from 2020)

Diagnosis, severity assessment, and therapy evaluation of amyloidosis using amyloid PET imaiging (Continued study from 2020) - Diagnosis, severity assessment, and therapy evaluation of amyloidosis using amyloid PET imaiging (Continued study from 2020)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042176

Enrollment

100

Registered

2020-10-19

Start date

2020-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyloidosis

Interventions

Amyloid PET examination is perfomed when diagnosis of amyloidosis is made. Patient who recieves treatment intervention requires sequential amyloid PET examinations after starting the treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any adult participant who is diagnosed as having amyloidosis.

Exclusion criteria

Exclusion criteria: Participant who doesn't agree to enroll the study.

Design outcomes

Primary

Measure	Time frame
Intensity of tracer uptake in each organ.	—

Countries

Japan

Contacts

Public ContactNagaaki Katoh

Shinshu University School of Medicine Department of Medicine (Neurology and Rheumatology)

nagaaki@shinshu-u.ac.jp0263-37-2673

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026